Ausgabe Sonderheft 1/1998
Inhalt (16 Artikel)
Clinical evaluation of biologically targeted drugs: Obstacles and opportunities
Anthony L. Boral, Scott Dessain, Bruce A. Chabner
Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein
Yuichi Sugiyama, Yukio Kato, Xiao-yan Chu
Preclinical approach for identifying drug interactions
Tetsuya Kamataki, Tsuyoshi Yokoi, Ken-ichi Fujita, Yuichi Ando
Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
Edward A. Sausville, Richard D. Lush, Donna Headlee, Adaline C. Smith, William D. Figg, Susan G. Arbuck, Adrian M. Senderowicz, Eiichi Fuse, Hiromi Tanii, Takashi Kuwabara, Satoshi Kobayashi
High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer
Martin S. Tallman, William J. Gradishar
Combined-modality treatment for stage IIIa (n2) non-small cell lung cancer: a national cancer institute intergroup study
David S. Ettinger
National Cancer Institute Clinical Trials Program in Colorectal Cancer
Barbara A. Conley, Richard S. Kaplan, Susan G. Arbuck
Cooperative oncology groups in Japan: Experience from the Japan Adult Leukemia Study Group
Ryuzo Ohno
European drug development and its impact on national activities: The Dutch example
Herbert M. Pinedo